New visual processing unit (VPU) with asymmetric waveforms for Retinitis Pigmentosa

Phase-Based Progress Estimates
University of Michigan, Ann Arbor, MIRetinitis PigmentosaNew visual processing unit (VPU) with asymmetric waveforms - Device
25 - 89
All Sexes
What conditions do you have?

Study Summary

This trial will test new ways to stimulate and train the retina in order to improve the vision of those with retinal prosthesis.

Eligible Conditions
  • Retinitis Pigmentosa

Treatment Effectiveness

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Baseline, 8 hours

Baseline, 8 hours
Change in shape perception
Percent change in stimulus thresholds

Trial Safety

Trial Design

1 Treatment Group

Retinal stimulation
1 of 1

Experimental Treatment

20 Total Participants · 1 Treatment Group

Primary Treatment: New visual processing unit (VPU) with asymmetric waveforms · No Placebo Group · N/A

Retinal stimulationExperimental Group · 2 Interventions: New visual processing unit (VPU) with asymmetric waveforms, New VPU with bipolar stimulation · Intervention Types: Device, Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 8 hours

Who is running the clinical trial?

University of MichiganLead Sponsor
1,647 Previous Clinical Trials
6,420,427 Total Patients Enrolled
3 Trials studying Retinitis Pigmentosa
555 Patients Enrolled for Retinitis Pigmentosa
National Eye Institute (NEI)NIH
520 Previous Clinical Trials
1,075,375 Total Patients Enrolled
22 Trials studying Retinitis Pigmentosa
14,334 Patients Enrolled for Retinitis Pigmentosa
James WeilandPrincipal Investigator - University of Michigan
University of Michigan

Eligibility Criteria

Age 25 - 89 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must have an Argus II Retinal Prosthesis implanted.

Who else is applying?

What state do they live in?
How old are they?
18 - 65100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%